Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Avosentan

Known as: 2-Pyridinesulfonamide, N-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl-, 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The last trials leading to licensed new drugs for renal protection in type 2 diabetes—RENAAL and IDNT— were reported 15 years ago… Expand
Is this relevant?
2014
2014
Multiple studies indicate that endothelin antagonism may have a protective effect for chronic kidney disease. Despite that… Expand
Is this relevant?
Review
2013
Review
2013
Numerous pre-clinical studies have implicated endothelin-1 in the pathogenesis of diabetic and non-diabetic chronic kidney… Expand
Is this relevant?
2012
2012
Several clinical studies have investigated the potential benefits of endothelin receptor antagonism in chronic pathologies such… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2012
Review
2012
Diabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease in western countries. This implies that… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
In the short term, the endothelin antagonist avosentan reduces proteinuria, but whether this translates to protection from… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Despite the first-line use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), there is… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Aims/hypothesisThere is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
In the present study, we evaluated the effect of simultaneously blocking angiotensin II synthesis and endothelin (ET)-1 activity… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2009
2009
The endothelin receptor antagonist avosentan may cause fluid overload at doses of 25 and 50 mg, but the actual mechanisms of this… Expand
  • figure 2
  • figure 1
  • table 1
  • figure 3
  • figure 4
Is this relevant?